HER-2/neu and p53 Expression Versus Tamoxifen Resistance in Estrogen Receptor–Positive, Node-Positive Breast Cancer

This publication has 18 references indexed in Scilit:

• Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer
  British Journal of Cancer, 1999
• Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein.
  Journal of Clinical Oncology, 1997
• Variation of hormonal receptor, pS2, c-erbB-2 and GSTπ contents in breast carcinomas under tamoxifen: a study of 74 cases
  British Journal of Cancer, 1996
• Relation of oestradiol-mediated growth stimulation with the expression of c-erbB-2 protein in xenotransplanted oestradiol-receptor-positive and -negative breast carcinomas
  Zeitschrift für Krebsforschung und Klinische Onkologie, 1996
• Oncogene amplification and prognosis in breast cancer: Relationship with systemic treatment
  Gene, 1995
• Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer.
  Journal of Clinical Oncology, 1995
• ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer
  Cancer Letters, 1994
• Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu
  Breast Cancer Research and Treatment, 1992
• Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer
  British Journal of Cancer, 1992
• Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with neu Oncogene
  Science, 1985